Synergetics sets lawyers on Alcon for bully-boy, anti-competitive antics
This article was originally published in Clinica
Synergetics USA has filed a civil antitrust lawsuit against ophthalmic powerhouse Alcon, accusing the latter of using underhand tactics to stave off competition.
You may also be interested in...
Pfizer has revealed launch plans for its Nyvepria pegfilgrastim biosimilar, shortly after receiving formal European Commission approval.
Oxford University/AstraZeneca’s COVID-19 vaccine cuts the spread of the virus by 60%, apart from having 70% efficacy in reducing infections in vaccinated individuals. While that is good news for their Indian partner, Serum Institute, the 90% efficacy shown in a subset due to a dosing error causes a dilemma.
After announcing positive topline Phase II results for its Alzheimer’s candidate late last year, Korea's GemVax releases additional data showing significant improvement in secondary outcomes, further raising expectations for the novel peptide drug.